CoChat
Sign Up
Cited by 26Glioma Diagnosis and TreatmentNeuroinflammation and Neurodegeneration MechanismsCancer, Hypoxia, and Metabolism

Multiple Faces of the Glioblastoma Microenvironment

Open access
Șovrea, Alina Simona, Boșca, Bianca, Melincovici, Carmen Stanca, Constantin, Anne-Marie, Crintea, Andreea, Mărginean, Mariana, Dronca, Eleonora, Jianu, Mihaela Elena +4 more·2022·International Journal of Molecular Sciences
DOI 10.3390/ijms23020595PMC PMC8775531
Open this paper in CoChat — free accountOpen PDF

Abstract

The tumor microenvironment is a highly dynamic accumulation of resident and infiltrating tumor cells, responsible for growth and invasion. The authors focused on the leading-edge concepts regarding the glioblastoma microenvironment. Due to the fact that the modern trend in the research and treatment of glioblastoma is represented by multiple approaches that target not only the primary tumor but also the neighboring tissue, the study of the microenvironment in the peritumoral tissue is an appealing direction for current and future therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23020595

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 157

  1. [1]Mostofa A.G. Punganuru S.R. Madala H.R. Al-Obaide M. Srivenugopal K.S. The Process and Regulatory Components of Inflammation in Brain Oncogenesis Biomolecules 2017 7 34 10.3390/biom7020034 28346397 PMC5485723 · DOI
  2. [2]Li Q.J. Cai J.Q. Liu C.Y. Evolving Molecular Genetics of Glioblastoma Chin. Med. J. 2016 129 464 471 10.4103/0366-6999.176065 26879021 PMC4800848 · DOI
  3. [3]Buruiană A. Florian Ș.I. Florian A.I. Timiș T.L. Mihu C.M. Miclăuș M. Oșan S. Hrapșa I. Cataniciu R.C. Farcaș M. The Roles of miRNA in Glioblastoma Tumor Cell Communication: Diplomatic and Aggressive Negotiations Int. J. Mol. Sci. 2020 21 1950 10.3390/ijms21061950 32178454 PMC7139390 · DOI
  4. [4]Deutschman C.S. Acute-phase responses and SIRS/MODS: The good, the bad, and the nebulous Crit. Care Med. 1998 26 1630 1631 10.1097/00003246-199810000-00007 9781714 · DOI
  5. [5]Virtuoso A. Giovannoni R. De Luca C. Gargano F. Cerasuolo M. Maggio N. Lavitrano M. Papa M. The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence Int. J. Mol. Sci. 2021 22 3301 10.3390/ijms22073301 33804873 PMC8036663 · DOI
  6. [6]Heddleston J.M. Li Z. McLendon R.E. Hjelmeland A.B. Rich J.N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype Cell Cycle 2009 8 3274 3284 10.4161/cc.8.20.9701 19770585 PMC2825672 · DOI · Paper page
  7. [7]Molina M.L. García-Bernal D. Martinez S. Valdor R. Autophagy in the Immunosuppressive Perivascular Microenvironment of Glioblastoma Cancers 2019 12 102 10.3390/cancers12010102 31906065 PMC7016956 · DOI
  8. [8]Chen Z. Hambardzumyan D. Immune Microenvironment in Glioblastoma Subtypes Front. Immunol. 2018 9 1004 10.3389/fimmu.2018.01004 29867979 PMC5951930 · DOI
  9. [9]Perrin S.L. Samuel M.S. Koszyca B. Brown M.P. Ebert L.M. Oksdath M. Gomez G.A. Glioblastoma heterogeneity and the tumour microenvironment: Implications for preclinical research and development of new treatments Biochem. Soc. Trans. 2019 47 625 638 10.1042/BST20180444 30902924 · DOI
  10. [10]Qiu R. Zhong Y. Li Q. Li Y. Fan H. Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors Front. Cell Dev. Biol. 2021 9 693215 10.3389/fcell.2021.693215 34211978 PMC8239469 · DOI
  11. [11]Haksoyler V. Besen A.A. Koseci T. Olgun P. Bayram E. Topkan E. Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan Biomark. Med. 2021 15 851 859 10.2217/bmm-2021-0271 33983042 · DOI
  12. [12]Zhang H. Zhou Y. Cui B. Liu Z. Shen H. Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma Biomed. Pharmacother. 2020 126 110086 10.1016/j.biopha.2020.110086 32172060 · DOI
  13. [13]Wang R. Chadalavada K. Wilshire J. Kowalik U. Hovinga K.E. Geber A. Fligelman B. Leversha M. Brennan C. Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium Nature 2010 468 829 833 10.1038/nature09624 21102433 · DOI
  14. [14]Ricci-Vitiani L. Pallini R. Biffoni M. Todaro M. Invernici G. Cenci T. Maira G. Parati E.A. Stassi G. Larocca L.M. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells Nature 2010 468 824 828 10.1038/nature09557 21102434 · DOI
  15. [15]Carmeliet P. Jain R.K. Molecular mechanisms and clinical applications of angiogenesis Nature 2011 473 298 307 10.1038/nature10144 21593862 PMC4049445 · DOI · Paper page
  16. [16]Aldape K. Zadeh G. Mansouri S. Reifenberger G. von Deimling A. Glioblastoma: Pathology, molecular mechanisms and markers Acta Neuropathol. 2015 129 829 848 10.1007/s00401-015-1432-1 25943888 · DOI · Paper page
  17. [17]Phillips H.S. Kharbanda S. Chen R. Forrest W.F. Soriano R.H. Wu T.D. Misra A. Nigro J.M. Colman H. Soroceanu L. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006 9 157 173 10.1016/j.ccr.2006.02.019 16530701 · DOI
  18. [18]Costello J.F. Plass C. Arap W. Chapman V.M. Held W.A. Berger M.S. Su Huang H.J. Cavenee W.K. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA Cancer Res. 1997 57 1250 1254 9102208
  19. [19]Jiao Y. Killela P.J. Reitman Z.J. Rasheed A.B. Heaphy C.M. de Wilde R.F. Rodriguez F.J. Rosemberg S. Oba-Shinjo S.M. Nagahashi Marie S.K. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas Oncotarget 2012 3 709 722 10.18632/oncotarget.588 22869205 PMC3443254 · DOI
  20. [20]Aquilanti E. Miller J. Santagata S. Cahill D.P. Brastianos P.K. Updates in prognostic markers for gliomas Neuro Oncol. 2018 20 (Suppl. S7) vii17 vii26 10.1093/neuonc/noy158 30412261 PMC6225747 · DOI
  21. [21]Deaton A.M. Bird A. CpG islands and the regulation of transcription Genes Dev. 2011 25 1010 1022 10.1101/gad.2037511 21576262 PMC3093116 · DOI · Paper page
  22. [22]Esteller M. Garcia-Foncillas J. Andion E. Goodman S.N. Hidalgo O.F. Vanaclocha V. Baylin S.B. Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N. Engl. J. Med. 2000 343 1350 1354 10.1056/NEJM200011093431901 11070098 · DOI
  23. [23]Hegi M.E. Diserens A.C. Godard S. Dietrich P.Y. Regli L. Ostermann S. Otten P. Van Melle G. de Tribolet N. Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin. Cancer Res. 2004 10 1871 1874 10.1158/1078-0432.CCR-03-0384 15041700 · DOI
  24. [24]Huang F.W. Hodis E. Xu M.J. Kryukov G.V. Chin L. Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma Science 2013 339 957 959 10.1126/science.1229259 23348506 PMC4423787 · DOI · Paper page
  25. [25]Ma X. Gong R. Wang R. Pan Y. Cai D. Pan B. Li Y. Xiang J. Li H. Zhang J. Recurrent TERT promoter mutations in non-small cell lung cancers Lung Cancer 2014 86 369 373 10.1016/j.lungcan.2014.10.009 25456736 · DOI
  26. [26]Crespo I. Vital A.L. Gonzalez-Tablas M. Patino Mdel C. Otero A. Lopes M.C. de Oliveira C. Domingues P. Orfao A. Tabernero M.D. Molecular and Genomic Alterations in Glioblastoma Multiforme Am. J. Pathol. 2015 185 1820 1833 10.1016/j.ajpath.2015.02.023 25976245 · DOI · Paper page
  27. [27]Weller M. Pfister S.M. Wick W. Hegi M.E. Reifenberger G. Stupp R. Molecular neuro-oncology in clinical practice: A new horizon Lancet Oncol. 2013 14 e370 e379 Erratum in Lancet Oncol. 2015, 16, e199 10.1016/S1470-2045(13)70168-2 23896276 · DOI
  28. [28]Ohgaki H. Dessen P. Jourde B. Horstmann S. Nishikawa T. Di Patre P.L. Burkhard C. Schüler D. Probst-Hensch N.M. Maiorka P.C. Genetic pathways to glioblastoma: A population-based study Cancer Res. 2004 64 6892 6899 10.1158/0008-5472.CAN-04-1337 15466178 · DOI
  29. [29]Rachakonda P.S. Hosen I. de Verdier P.J. Fallah M. Heidenreich B. Ryk C. Wiklund N.P. Steineck G. Schadendorf D. Hemminki K. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism Proc. Natl. Acad. Sci. USA 2013 110 17426 17431 10.1073/pnas.1310522110 24101484 PMC3808633 · DOI
  30. [30]Lee S.E. Chang S.H. Kim W.Y. Lim S.D. Kim W.S. Hwang T.S. Han H.S. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma Oncotarget 2016 7 69267 69275 10.18632/oncotarget.12121 27661004 PMC5342476 · DOI
  31. [31]Labussière M. Boisselier B. Mokhtari K. Di Stefano A.L. Rahimian A. Rossetto M. Ciccarino P. Saulnier O. Paterra R. Marie Y. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes Neurology 2014 83 1200 1206 10.1212/WNL.0000000000000814 25150284 · DOI
  32. [33]Karremann M. Gielen G.H. Hoffmann M. Wiese M. Colditz N. Warmuth-Metz M. Bison B. Claviez A. van Vuurden D.G. von Bueren A.O. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location Neuro Oncol. 2018 20 123 131 10.1093/neuonc/nox149 29016894 PMC5761525 · DOI
  33. [34]Ryall S. Krishnatry R. Arnoldo A. Buczkowicz P. Mistry M. Siddaway R. Ling C. Pajovic S. Yu M. Rubin J.B. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma Acta Neuropathol. Commun. 2016 4 93 10.1186/s40478-016-0353-0 27577993 PMC5006436 · DOI
  34. [35]Meyronet D. Esteban-Mader M. Bonnet C. Joly M.O. Uro-Coste E. Amiel-Benouaich A. Forest F. Rousselot-Denis C. Burel-Vandenbos F. Bourg V. Characteristics of H3 K27M-mutant gliomas in adults Neuro Oncol. 2017 19 1127 1134 10.1093/neuonc/now274 28201752 PMC5570304 · DOI
  35. [36]Sochocka M. Diniz B.S. Leszek J. Inflammatory Response in the CNS: Friend or Foe? Mol. Neurobiol. 2017 54 8071 8089 10.1007/s12035-016-0297-1 27889895 PMC5684251 · DOI · Paper page
  36. [37]Perng P. Lim M. Immunosuppressive mechanisms of malignant gliomas: Parallels at non-CNS sites Front. Oncol. 2015 5 153 10.3389/fonc.2015.00153 26217588 PMC4492080 · DOI
  37. [38]Colotta F. Allavena P. Sica A. Garlanda C. Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability Carcinogenesis 2009 30 1073 1081 10.1093/carcin/bgp127 19468060 · DOI
  38. [39]Mesfin F.B. Al-Dhahir M.A. Gliomas StatPearls Publishing Treasure Island, FL, USA 2021 Available online: https://www.ncbi.nlm.nih.gov/books/NBK441874/ (accessed on 11 December 2021)
  39. [40]Dharmajaya R. Sari D.K. Role and value of inflammatory markers in brain tumors: A case-controlled study Ann. Med. Surg. 2021 63 102107 10.1016/j.amsu.2021.01.055 PMC7890138 33659053 · DOI
  40. [41]Jackson C.M. Choi J. Lim M. Mechanisms of immunotherapy resistance: Lessons from glioblastoma Nat. Immunol. 2019 20 1100 1109 10.1038/s41590-019-0433-y 31358997 · DOI
  41. [42]Okolie O. Bago J.R. Schmid R.S. Irvin D.M. Bash R.E. Miller C.R. Hingtgen S.D. Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model Neuro Oncol. 2016 18 1622 1633 10.1093/neuonc/now117 27298311 PMC5791515 · DOI
  42. [43]Albulescu R. Codrici E. Popescu I.D. Mihai S. Necula L.G. Petrescu D. Teodoru M. Tanase C.P. Cytokine patterns in brain tumour progression Mediat. Inflamm. 2013 2013 979748 10.1155/2013/979748 PMC3707225 23864770 · DOI
  43. [44]Li T. Chen X. Zhang C. Zhang Y. Yao W. An update on reactive astrocytes in chronic pain J. Neuroinflamm. 2019 16 140 10.1186/s12974-019-1524-2 PMC6615111 31288837 · DOI
  44. [45]O’Brien E.R. Howarth C. Sibson N.R. The role of astrocytes in CNS tumors: Pre-clinical models and novel imaging approaches Front. Cell. Neurosci. 2013 7 40 10.3389/fncel.2013.00040 23596394 PMC3627137 · DOI
  45. [46]Mitchell D. Shireman J. Sierra Potchanant E.A. Lara-Velazquez M. Dey M. Neuroinflammation in Autoimmune Disease and Primary Brain Tumors: The Quest for Striking the Right Balance Front. Cell. Neurosci. 2021 15 716947 10.3389/fncel.2021.716947 34483843 PMC8414998 · DOI
  46. [47]Zhu V.F. Jingxuan Y. Drake G.L.B. Min L. Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis Cancer Lett. 2012 316 139 150 10.1016/j.canlet.2011.11.001 22075379 · DOI
  47. [48]Dranoff G. Cytokines in cancer pathogenesis and cancer therapy Nat. Rev. Cancer 2004 4 11 22 10.1038/nrc1252 14708024 · DOI
  48. [49]Bunevicius A. Radziunas A. Tamasauskas S. Tamasauskas A. Laws E.R. Iervasi G. Bunevicius R. Deltuva V. Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients J. Neurooncol. 2018 138 351 358 10.1007/s11060-018-2803-y 29460097 · DOI
  49. [50]Brunner C. Seiderer J. Schlamp A. Bidlingmaier M. Eigler A. Haimerl W. Lehr H.A. Krieg A.M. Hartmann G. Endres S. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo J. Immunol. 2000 165 6278 6286 10.4049/jimmunol.165.11.6278 11086063 · DOI
  50. [51]Yoshida S. Ono M. Shono T. Izumi H. Ishibashi T. Suzuki H. Kuwano M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis Mol. Cell. Biol. 1997 17 4015 4023 10.1128/MCB.17.7.4015 9199336 PMC232254 · DOI
  51. [52]Ghosh S. Paul A. Sen E. Tumor necrosis factor α-induced hypoxia-inducible factor 1α-β-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling Mol. Cell. Biol. 2013 33 2718 2731 10.1128/MCB.01254-12 23671189 PMC3700138 · DOI
  52. [53]Fukaya R. Ohta S. Yaguchi T. Matsuzaki Y. Sugihara E. Okano H. Saya H. Kawakami Y. Kawase T. Yoshida K. MIF Maintains the Tumorigenic Capacity of Brain Tumor-Initiating Cells by Directly Inhibiting p53 Cancer Res. 2016 76 2813 2823 10.1158/0008-5472.CAN-15-1011 26980763 · DOI
  53. [54]Veillat V. Carli C. Metz C.N. Al-Abed Y. Naccache P.H. Akoum A. Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74, and MAPK signaling pathways J. Clin. Endocrinol. Metab. 2010 95 E403 E412 10.1210/jc.2010-0417 20829186 · DOI
  54. [55]Munaut C. Boniver J. Foidart J.-M. Deprez M. Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression Neuropathol. Appl. Neurobiol. 2002 28 452 460 10.1046/j.1365-2990.2002.00416.x 12445161 · DOI
  55. [56]Apte R.N. Dotan S. Elkabets M. White M.R. Reich E. Carmi Y. Song X. Dvozkin T. Krelin Y. Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions Cancer Metastasis Rev. 2006 25 387 408 10.1007/s10555-006-9004-4 17043764 · DOI
  56. [57]Paugh B.S. Bryan L. Paugh S.W. Wilczynska K.M. Alvarez S.M. Singh S.K. Kapitonov D. Rokita H. Wright S. Griswold-Prenner I. Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells J. Biol. Chem. 2009 284 3408 3417 10.1074/jbc.M807170200 19074142 PMC2635028 · DOI
  57. [58]Wang L. Liu Z. Balivada S. Shrestha T. Bossmann S. Pyle M. Pappan L. Shi J. Troyer D. Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells Stem Cell Res. Ther. 2012 3 5 10.1186/scrt96 22330721 PMC3340549 · DOI
  58. [59]Goswami S. Gupta A. Sharma S.K. Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG J. Neurochem. 1998 71 1837 1845 10.1046/j.1471-4159.1998.71051837.x 9798907 · DOI
  59. [60]Wang H. Lathia J.D. Wu Q. Wang J. Li Z. Heddleston J.M. Eyler C.E. Elderbroom J. Gallagher J. Schuschu J. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth Stem Cells 2009 27 2393 2404 10.1002/stem.188 19658188 PMC2825688 · DOI
  60. [61]Li R. Li G. Deng L. Liu Q. Dai J. Shen J. Zhang J. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1 Oncol. Rep. 2010 23 1553 1559 10.3892/or_00000795 20428809 · DOI
  61. [62]Graf M.R. Prins R.M. Merchant R.E. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity J. Immunol. 2001 166 121 129 10.4049/jimmunol.166.1.121 11123284 · DOI
  62. [63]Weissenberger J. Loeffler S. Kappeler A. Kopf M. Lukes A. Afanasieva T.A. Aguzzi A. Weis J. IL-6 is required for glioma development in a mouse model Oncogene 2004 23 3308 3316 10.1038/sj.onc.1207455 15064729 · DOI
  63. [65]Brat D.J. Bellail A.C. Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis Neuro Oncol. 2005 7 122 133 10.1215/S1152851704001061 15831231 PMC1871893 · DOI
  64. [66]Raychaudhuri B. Vogelbaum M.A. IL-8 is a mediator of NF-κB induced invasion by gliomas J. Neurooncol. 2011 101 227 235 10.1007/s11060-010-0261-2 20577780 · DOI
  65. [67]Carlsson A. Persson O. Ingvarsson J. Widegren B. Salford L. Borrebaeck C.A.K. Wingren C. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients Proteomics Clin. Appl. 2010 4 591 602 10.1002/prca.200900173 21137077 · DOI
  66. [68]Samaras V. Piperi C. Levidou G. Zisakis A. Kavantzas N. Themistocleous M.S. Boviatsis E.I. Barbatis C. Lea R.W. Kalofoutis A. Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry Hum. Immunol. 2009 70 391 397 10.1016/j.humimm.2009.03.011 19332096 · DOI
  67. [69]De la Iglesia N. Konopka G. Lim K.-L. Nutt C.L. Bromberg J.F. Frank D.A. Mischel P.S. Louis D.N. Bonni A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness J. Neurosci. 2008 28 5870 5878 10.1523/JNEUROSCI.5385-07.2008 18524891 PMC2700037 · DOI
  68. [70]De Boeck A. Ahn B.Y. D’Mello C. Lun X. Menon S.V. Alshehri M.M. Szulzewsky F. Shen Y. Khan L. Dang N.H. Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression Nat. Commun. 2020 11 4997 10.1038/s41467-020-18569-4 33020472 PMC7536425 · DOI
  69. [71]Lu Y. Jiang F. Zheng X. Katakowski M. Buller B. To S.-S.T. Chopp M. TGF-β1 promotes motility and invasiveness of glioma cells through activation of ADAM17 Oncol. Rep. 2011 25 1329 1335 10.3892/or.2011.1195 21359495 PMC3070292 · DOI
  70. [72]Grauer O. Pöschl P. Lohmeier A. Adema G.J. Bogdahn U. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2 J. Neurooncol. 2007 82 151 161 10.1007/s11060-006-9274-2 17106649 · DOI
  71. [73]Llopiz D. Dotor J. Casares N. Bezunartea J. Díaz-Valdés N. Ruiz M. Aranda F. Berraondo P. Prieto J. Lasarte J.J. Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy Int. J. Cancer 2009 125 2614 2623 10.1002/ijc.24656 19530254 · DOI
  72. [74]Sanchez-Perez Y. Soto-Reyes E. Garcia-Cuellar C.M. Cacho-Diaz B. Santamaria A. Rangel-Lopez E. Role of Epigenetics and Oxidative Stress in Gliomagenesis CNS Neurol. Disord. Drug Targets 2017 16 1090 1098 10.2174/1871527317666180110124645 29318979 · DOI
  73. [75]Iida T. Furuta A. Kawashima M. Nishida J. Nakabeppu Y. Iwaki T. Accumulation of 8-oxo-2′-deoxyguanosine and increased expression of hMTH1 protein in brain tumors Neuro Oncol. 2001 3 73 81 10.1093/neuonc/3.2.73 11296483 PMC1920610 · DOI
  74. [76]Leung S.Y. Yuen S.T. Chan T.L. Chan A.S. Ho J.W. Kwan K. Fan Y.W. Hung K.N. Chung L.P. Wyllie A.H. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation Oncogene 2000 19 4079 4083 10.1038/sj.onc.1203740 10962567 · DOI
  75. [77]Nitta M. Kozono D. Kennedy R. Stommel J. Ng K. Zinn P.O. Kushwaha D. Kesari S. Inda M.-M. Wykosky J. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy PLoS ONE 2010 5 e10767 10.1371/journal.pone.0010767 20532243 PMC2879424 · DOI
  76. [78]See A.P. Han J.E. Phallen J. Binder Z. Gallia G. Pan F. Jinasena D. Jackson C. Belcaid Z. Jeong S.J. The role of STAT3 activation in modulating the immune microenvironment of GBM J. Neurooncol. 2012 110 359 368 10.1007/s11060-012-0981-6 23096132 PMC3700337 · DOI
  77. [79]Rink C. Khanna S. Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke Antioxid. Redox Signal. 2011 14 1889 1903 10.1089/ars.2010.3474 20673202 PMC3078506 · DOI · Paper page
  78. [80]Beppu T. Kamada K. Yoshida Y. Arai H. Ogasawara K. Ogawa A. Change of oxygen pressure in glioblastoma tissue under various conditions J. Neurooncol. 2002 58 47 52 10.1023/A:1015832726054 12160140 · DOI
  79. [81]Rong Y. Durden D.L. Van Meir E.G. Brat D.J. ‘Pseudopalisading’ necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis J. Neuropathol. Exp. Neurol. 2006 65 529 539 10.1097/00005072-200606000-00001 16783163 · DOI
  80. [82]Jensen R.L. Mumert M.L. Gillespie D.L. Kinney A.Y. Schabel M.C. Salzman K.L. Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome Neuro Oncol. 2014 16 280 291 10.1093/neuonc/not148 24305704 PMC3895375 · DOI
  81. [83]Kaur B. Khwaja F.W. Severson E.A. Matheny S.L. Brat D.J. Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis Neuro Oncol. 2005 7 134 153 10.1215/S1152851704001115 15831232 PMC1871894 · DOI · Paper page
  82. [85]Nusblat L.M. Tanna S. Roth C.M. Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotype Cancer Drug Resist. 2020 3 199 208 10.20517/cdr.2019.96 32566921 PMC7304423 · DOI
  83. [86]Jewell U.R. Kvietikova I. Scheid A. Bauer C. Wenger R.H. Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous FASEB J. 2001 15 1312 1314 10.1096/fj.00-0732fje 11344124 · DOI
  84. [87]Majmundar A.J. Wong W.J. Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress Mol. Cell 2010 40 294 309 10.1016/j.molcel.2010.09.022 20965423 PMC3143508 · DOI · Paper page
  85. [89]Holland E.C. Hively W.P. DePinho R.A. Varmus H.E. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice Genes Dev. 1998 12 3675 3685 10.1101/gad.12.23.3675 9851974 PMC317252 · DOI
  86. [90]Zhang Z. Yao L. Yang J. Wang Z. Du G. PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia (Review) Mol. Med. Rep. 2018 18 3547 3554 10.3892/mmr.2018.9375 30106145 PMC6131612 · DOI
  87. [91]Ma J. Sawai H. Matsuo Y. Ochi N. Yasuda A. Takahashi H. Wakasugi T. Funahashi H. Sato M. Takeyama H. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells J. Surg. Res. 2010 160 90 101 10.1016/j.jss.2008.08.016 19560785 · DOI
  88. [92]Iwakuma T. Lozano G. MDM2, an introduction Mol. Cancer Res. 2003 1 993 1000 14707282
  89. [93]Nieminen A.L. Qanungo S. Schneider E.A. Jiang B.H. Agani F.H. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia J. Cell Physiol. 2005 204 364 369 10.1002/jcp.20406 15880652 · DOI
  90. [94]Li L.C. Zhang M. Feng Y.K. Wang X.J. IDH1-R132H Suppresses Glioblastoma Malignancy through FAT1-ROS-HIF-1α Signaling Neurol. India 2020 68 1050 1058 10.4103/0028-3886.294557 33109851 · DOI
  91. [95]Madan E. Dikshit B. Gowda S.H. Srivastava C. Sarkar C. Chattopadhyay P. Sinha S. Chosdol K. FAT1 is a novel upstream regulator of HIF1α and invasion of high-grade glioma Int. J. Cancer 2016 139 2570 2582 10.1002/ijc.30386 27536856 PMC6585695 · DOI
  92. [96]Chosdol K. Misra A. Puri S. Srivastava T. Chattopadhyay P. Sarkar C. Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene ‘FAT’ in human astrocytic tumors BMC Cancer 2009 9 5 10.1186/1471-2407-9-5 19126244 PMC2631005 · DOI
  93. [97]Patel A.P. Tirosh I. Trombetta J.J. Shalek A.K. Gillespie S.M. Wakimoto H. Cahill D.P. Nahed B.V. Curry W.T. Martuza R.L. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma Science 2014 344 1396 1401 10.1126/science.1254257 24925914 PMC4123637 · DOI · Paper page
  94. [98]Meyer M. Reimand J. Lan X. Head R. Zhu X. Kushida M. Bayani J. Pressey J.C. Lionel A.C. Clarke I.D. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity Proc. Natl. Acad. Sci. USA 2015 112 851 856 10.1073/pnas.1320611111 25561528 PMC4311802 · DOI
  95. [99]Zhao Y. Carter R. Natarajan S. Varn F.S. Compton D.A. Gawad C. Cheng C. Godek K.M. Single-cell RNA sequencing reveals the impact of chromosomal instability on glioblastoma cancer stem cells BMC Med. Genom. 2019 12 79 10.1186/s12920-019-0532-5 PMC6545015 31151460 · DOI
  96. [102]Ishii A. Kimura T. Sadahiro H. Kawano H. Takubo K. Suzuki M. Ikeda E. Histological Characterization of the Tumorigenic “Peri-Necrotic Niche” Harboring Quiescent Stem-Like Tumor Cells in Glioblastoma PLoS ONE 2016 11 e0147366 10.1371/journal.pone.0147366 26799577 PMC4723051 · DOI
  97. [103]Aderetti D.A. Hira V. Molenaar R.J. van Noorden C. The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma Biochim. Biophys. Acta Rev. Cancer 2018 1869 346 354 10.1016/j.bbcan.2018.04.008 29684521 · DOI
  98. [104]Zeng X. Wang Q. Tan X. Jia L. Li Y. Hu M. Zhang Z. Bai X. Zhu Y. Yang X. Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma J. Nanobiotechnol. 2019 17 47 10.1186/s12951-019-0483-1 30935403 PMC6442425 · DOI
  99. [105]Codrici E. Enciu A.M. Popescu I.D. Mihai S. Tanase C. Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets Stem Cells Int. 2016 2016 5728438 10.1155/2016/5728438 26977157 PMC4764748 · DOI
  100. [106]Mergenthaler P. Lindauer U. Dienel G.A. Meisel A. Sugar for the brain: The role of glucose in physiological and pathological brain function Trends Neurosci. 2013 36 587 597 10.1016/j.tins.2013.07.001 23968694 PMC3900881 · DOI · Paper page
  101. [107]Tieu M.T. Lovblom L.E. McNamara M.G. Mason W. Laperriere N. Millar B.A. Ménard C. Kiehl T.R. Perkins B.A. Chung C. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide J. Neurooncol. 2015 124 119 126 10.1007/s11060-015-1815-0 26015297 PMC4498235 · DOI
  102. [108]Bao Z. Chen K. Krepel S. Tang P. Gong W. Zhang M. Liang W. Trivett A. Zhou M. Wang J.M. High Glucose Promotes Human Glioblastoma Cell Growth by Increasing the Expression and Function of Chemoattractant and Growth Factor Receptors Transl. Oncol. 2019 12 1155 1163 10.1016/j.tranon.2019.04.016 31207546 PMC6580091 · DOI
  103. [109]Hsu P.P. Sabatini D.M. Cancer cell metabolism: Warburg and beyond Cell 2008 134 703 707 10.1016/j.cell.2008.08.021 18775299 · DOI · Paper page
  104. [110]Liberti M.V. Locasale J.W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 2016 41 211 218 10.1016/j.tibs.2015.12.001 26778478 PMC4783224 · DOI · Paper page
  105. [111]Locasale J.W. Cantley L.C. Metabolic flux and the regulation of mammalian cell growth Cell Metab. 2011 14 443 451 10.1016/j.cmet.2011.07.014 21982705 PMC3196640 · DOI · Paper page
  106. [112]Chang C.H. Qiu J. O’Sullivan D. Buck M.D. Noguchi T. Curtis J.D. Chen Q. Gindin M. Gubin M.M. van der Windt G.J. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression Cell 2015 162 1229 1241 10.1016/j.cell.2015.08.016 26321679 PMC4864363 · DOI · Paper page
  107. [113]Kucharzewska P. Christianson H.C. Belting M. Global profiling of metabolic adaptation to hypoxic stress in human glioblastoma cells PLoS ONE 2015 10 e0116740 10.1371/journal.pone.0116740 25633823 PMC4310608 · DOI
  108. [114]Kim J.W. Tchernyshyov I. Semenza G.L. Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia Cell Metab. 2006 3 177 185 10.1016/j.cmet.2006.02.002 16517405 · DOI · Paper page
  109. [115]Papandreou I. Cairns R.A. Fontana L. Lim A.L. Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption Cell Metab. 2006 3 187 197 10.1016/j.cmet.2006.01.012 16517406 · DOI · Paper page
  110. [116]Dimmer K.S. Friedrich B. Lang F. Deitmer J.W. Bröer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells Biochem. J. 2000 350 219 227 10.1042/bj3500219 10926847 PMC1221245 · DOI
  111. [117]Bartrons R. Simon-Molas H. Rodríguez-García A. Castaño E. Navarro-Sabaté À. Manzano A. Martinez-Outschoorn U.E. Fructose 2,6-Bisphosphate in Cancer Cell Metabolism Front. Oncol. 2018 8 331 10.3389/fonc.2018.00331 30234009 PMC6131595 · DOI
  112. [118]Schulze A. Harris A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption Nature 2012 491 364 373 10.1038/nature11706 23151579 · DOI
  113. [119]Kalyanaraman B. Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism Redox Biol. 2017 12 833 842 10.1016/j.redox.2017.04.018 28448945 PMC5406543 · DOI
  114. [120]Niimi N. Yako H. Takaku S. Chung S.K. Sango K. Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems Int. J. Mol. Sci. 2021 22 1031 10.3390/ijms22031031 33494154 PMC7864348 · DOI
  115. [122]Pereira E.R. Frudd K. Awad W. Hendershot L.M. Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF) J. Biol. Chem. 2014 289 3352 3364 10.1074/jbc.M113.507194 24347168 PMC3916539 · DOI
  116. [123]Krawczynski K. Godlewski J. Bronisz A. Oxidative Stress-Part of the Solution or Part of the Problem in the Hypoxic Environment of a Brain Tumor Antioxidants 2020 9 747 10.3390/antiox9080747 PMC7464568 32823815 · DOI
  117. [124]Strickland M. Stoll E.A. Metabolic Reprogramming in Glioma Front. Cell Dev. Biol. 2017 5 43 10.3389/fcell.2017.00043 28491867 PMC5405080 · DOI
  118. [125]Lin H. Patel S. Affleck V.S. Wilson I. Turnbull D.M. Joshi A.R. Maxwell R. Stoll E.A. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells Neuro Oncol. 2017 19 43 54 10.1093/neuonc/now128 27365097 PMC5193020 · DOI
  119. [126]Delikatny E.J. Chawla S. Leung D.J. Poptani H. MR-visible lipids and the tumor microenvironment NMR Biomed. 2011 24 592 611 10.1002/nbm.1661 21538631 PMC3640643 · DOI
  120. [127]Menard J.A. Christianson H.C. Kucharzewska P. Bourseau-Guilmain E. Svensson K.J. Lindqvist E. Indira Chandran V. Kjellén L. Welinder C. Bengzon J. Metastasis Stimulation by Hypoxia and Acidosis-Induced Extracellular Lipid Uptake Is Mediated by Proteoglycan-Dependent Endocytosis Cancer Res. 2016 76 4828 4840 10.1158/0008-5472.CAN-15-2831 27199348 · DOI
  121. [128]Zaidi N. Lupien L. Kuemmerle N.B. Kinlaw W.B. Swinnen J.V. Smans K. Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids Prog. Lipid Res. 2013 52 585 589 10.1016/j.plipres.2013.08.005 24001676 PMC4002264 · DOI
  122. [129]Pirmoradi L. Seyfizadeh N. Ghavami S. Zeki A.A. Shojaei S. Targeting cholesterol metabolism in glioblastoma: A new therapeutic approach in cancer therapy J. Investig. Med. 2019 67 715 719 10.1136/jim-2018-000962 30765502 · DOI
  123. [130]Barber C.N. Raben D.M. Lipid Metabolism Crosstalk in the Brain: Glia and Neurons Front. Cell. Neurosci. 2019 13 212 10.3389/fncel.2019.00212 31164804 PMC6536584 · DOI · Paper page
  124. [131]Kambach D.M. Halim A.S. Cauer A.G. Sun Q. Tristan C.A. Celiku O. Kesarwala A.H. Shankavaram U. Batchelor E. Stommel J.M. Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma Oncotarget 2017 8 14860 14875 10.18632/oncotarget.14740 28118603 PMC5362450 · DOI
  125. [132]Ahmad F. Sun Q. Patel D. Stommel J.M. Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma Cancers 2019 11 146 10.3390/cancers11020146 30691162 PMC6406281 · DOI
  126. [133]Villa G.R. Hulce J.J. Zanca C. Bi J. Ikegami S. Cahill G.L. Gu Y. Lum K.M. Masui K. Yang H. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers Cancer Cell 2016 30 683 693 10.1016/j.ccell.2016.09.008 27746144 PMC5479636 · DOI
  127. [134]Lieu E.L. Nguyen T. Rhyne S. Kim J. Amino acids in cancer Exp. Mol. Med. 2020 52 15 30 10.1038/s12276-020-0375-3 31980738 PMC7000687 · DOI
  128. [135]Reeds P.J. Dispensable and indispensable amino acids for humans J. Nutr. 2000 130 1835S 1840S 10.1093/jn/130.7.1835S 10867060 · DOI
  129. [138]Mayers J.R. Torrence M.E. Danai L.V. Papagiannakopoulos T. Davidson S.M. Bauer M.R. Lau A.N. Ji B.W. Dixit P.D. Hosios A.M. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers Science 2016 353 1161 1165 10.1126/science.aaf5171 27609895 PMC5245791 · DOI · Paper page
  130. [139]Ananieva E.A. Wilkinson A.C. Branched-chain amino acid metabolism in cancer Curr. Opin. Clin. Nutr. Metab. Care 2018 21 64 70 10.1097/MCO.0000000000000430 29211698 PMC5732628 · DOI
  131. [140]Zhang B. Chen Y. Shi X. Zhou M. Bao L. Hatanpaa K.J. Patel T. DeBerardinis R.J. Wang Y. Luo W. Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma Cell. Mol. Life Sci. 2021 78 195 206 10.1007/s00018-020-03483-1 32088728 PMC8112551 · DOI
  132. [141]Srivastava C. Irshad K. Dikshit B. Chattopadhyay P. Sarkar C. Gupta D.K. Sinha S. Chosdol K. FAT1 modulates EMT and stemness genes expression in hypoxic glioblastoma Int. J. Cancer 2018 142 805 812 10.1002/ijc.31092 28994107 · DOI
  133. [142]Gu Z. Cui X. Sun P. Wang X. Regulatory Roles of Tumor Necrosis Factor-α-Induced Protein 8 Like-Protein 2 in Inflammation, Immunity and Cancers: A Review Cancer Manag. Res. 2020 12 12735 12746 10.2147/CMAR.S283877 33364825 PMC7751774 · DOI
  134. [143]Bhagat M. Palanichamy J.K. Ramalingam P. Mudassir M. Irshad K. Chosdol K. Sarkar C. Seth P. Goswami S. Sinha S. HIF-2α mediates a marked increase in migration and stemness characteristics in a subset of glioma cells under hypoxia by activating an Oct-4/Sox-2-Mena (INV) axis Int. J. Biochem. Cell Biol. 2016 74 60 71 10.1016/j.biocel.2016.02.017 26923292 · DOI
  135. [144]Sun H. Gong S. Carmody R.J. Hilliard A. Li L. Sun J. Kong L. Xu L. Hilliard B. Hu S. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis Cell 2008 133 415 426 10.1016/j.cell.2008.03.026 18455983 PMC2398615 · DOI
  136. [145]Cao X. Zhang L. Shi Y. Sun Y. Dai S. Guo C. Zhu F. Wang Q. Wang J. Wang X. Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1 Mol. Cancer 2013 12 149 10.1186/1476-4598-12-149 24274578 PMC4176125 · DOI
  137. [146]Li Y. Li X. Liu G. Sun R. Wang L. Wang J. Wang H. Downregulated TIPE2 is associated with poor prognosis and promotes cell proliferation in non-small cell lung cancer Biochem. Biophys. Res. Commun. 2015 457 43 49 10.1016/j.bbrc.2014.12.080 25542151 · DOI
  138. [147]Liu Z.J. Liu H.L. Zhou H.C. Wang G.C. TIPE2 Inhibits Hypoxia-Induced Wnt/β-Catenin Pathway Activation and EMT in Glioma Cells Oncol. Res. 2016 24 255 261 10.3727/096504016X14666990347356 27656836 PMC7838627 · DOI
  139. [149]Busuioc C. Ciocan-Cartita C.A. Braicu C. Zanoaga O. Raduly L. Trif M. Muresan M.S. Ionescu C. Stefan C. Crivii C. Epithelial-Mesenchymal Transition Gene Signature Related to Prognostic in Colon Adenocarcinoma J. Pers. Med. 2021 11 476 10.3390/jpm11060476 34073426 PMC8229043 · DOI
  140. [150]Weathers S.P. de Groot J. VEGF Manipulation in Glioblastoma Oncology 2015 29 720 727 26470893
  141. [151]Yi Y. Hsieh I.Y. Huang X. Li J. Zhao W. Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy Front. Pharmacol. 2016 7 477 10.3389/fphar.2016.00477 28003805 PMC5141588 · DOI
  142. [153]Angara K. Rashid M.H. Shankar A. Ara R. Iskander A. Borin T.F. Jain M. Achyut B.R. Arbab A.S. Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies Histol. Histopathol. 2017 32 917 928 10.14670/HH-11-856 27990624 PMC5476524 · DOI
  143. [154]Melincovici C.S. Boşca A.B. Şuşman S. Mărginean M. Mihu C. Istrate M. Moldovan I.M. Roman A.L. Mihu C.M. Vascular endothelial growth factor (VEGF)—Key factor in normal and pathological angiogenesis Rom. J. Morphol. Embryol. 2018 59 455 467 30173249
  144. [155]Tena-Suck M.L. Celis-Lopez M.A. Collado-Ortiz M.A. Castillejos-Lopez M. Tenorio-Serralta M. Glioblastoma Multiforme and Angiogenesis: A Clinicopathological and Immunohistochemistry Approach J. Neurol. Res. 2015 5 199 206 10.14740/jnr337w · DOI
  145. [157]Ahir B.K. Engelhard H.H. Lakka S.S. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma Mol. Neurobiol. 2020 57 2461 2478 10.1007/s12035-020-01892-8 32152825 PMC7170819 · DOI
  146. [158]Kioi M. Vogel H. Schultz G. Hoffman R.M. Harsh G.R. Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice J. Clin. Investig. 2010 120 694 705 10.1172/JCI40283 20179352 PMC2827954 · DOI
  147. [159]Mao J.M. Liu J. Guo G. Mao X.G. Li C.X. Glioblastoma vasculogenic mimicry: Signaling pathways progression and potential anti-angiogenesis targets Biomark. Res. 2015 3 8 10.1186/s40364-015-0034-3 26085929 PMC4469398 · DOI
  148. [160]Pearson J.R.D. Regad T. Targeting cellular pathways in glioblastoma multiforme Signal Transduct. Target Ther. 2017 2 17040 10.1038/sigtrans.2017.40 29263927 PMC5661637 · DOI
  149. [161]Brat D.J. Castellano-Sanchez A. Kaur B. Van Meir E.G. Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation Adv. Anat. Pathol. 2002 9 24 36 10.1097/00125480-200201000-00004 11756757 · DOI
  150. [162]Atzori M.G. Tentori L. Ruffini F. Ceci C. Bonanno E. Scimeca M. Lacal P.M. Graziani G. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo J. Pharmacol. Exp. Ther. 2018 364 77 86 10.1124/jpet.117.244434 29025978 · DOI
  151. [163]Plate K.H. Mechanisms of Angiogenesis in the Brain J. Neuropathol. Exp. Neurol. 1999 58 313 320 10.1097/00005072-199904000-00001 10218626 · DOI
  152. [164]Hundsberger T. Reardon D.A. Wen P.Y. Angiogenesis inhibitors in tackling recurrent glioblastoma Expert Rev. Anticancer Ther. 2017 17 507 515 10.1080/14737140.2017.1322903 28438066 · DOI
  153. [165]Marcus H.J. Carpenter K.L. Price S.J. Hutchinson P.J. In vivo assessment of high-grade glioma biochemistry using microdialysis: A study of energy-related molecules, growth factors and cytokines J. Neurooncol. 2010 97 11 23 10.1007/s11060-009-9990-5 19714445 · DOI
  154. [166]Du R. Petritsch C. Lu K. Liu P. Haller A. Ganss R. Song H. Vandenberg S. Bergers G. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM Neuro Oncol. 2008 10 254 264 10.1215/15228517-2008-001 18359864 PMC2563048 · DOI
  155. [167]Xue Q. Cao L. Chen X.Y. Zhao J. Gao L. Li S.Z. Fei Z. High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates Oncol. Lett. 2017 13 1325 1330 10.3892/ol.2017.5567 28454256 PMC5403257 · DOI
  156. [168]Das S. Marsden P.A. Angiogenesis in Glioblastoma N. Engl. J. Med. 2013 369 1561 1563 10.1056/NEJMcibr1309402 24131182 PMC5378489 · DOI
  157. [169]Batchelor T.T. Sorensen A.G. di Tomaso E. Zhang W.T. Duda D.G. Cohen K.S. Kozak K.R. Cahill D.P. Chen P.J. Zhu M. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 2007 11 83 95 10.1016/j.ccr.2006.11.021 17222792 PMC2748664 · DOI · Paper page

Cited by

Sorted by citations

Authors
Șovrea, A. S., Boșca, B., Melincovici, C. S., Constantin, A.-M., Crintea, A., Mărginean, M., Dronca, E., Jianu, M. E., Suflețel, R., Gonciar, D., Bungărdean, M., & Crivii, C.-B.
Affiliations
  • Histology Discipline, Morphological Sciences Department, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania
  • Iuliu Hațieganu University of Medicine and Pharmacy (RO)
  • Pathological Anatomy Discipline, Morphological Sciences Department, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania
Corresponding author
  • Dronca, Eleonora
  • Crivii, Carmen-Bianca
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-01-06
Volume
23
Issue
2
Pages
595
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms23020595
PMC
PMC8775531
OpenAlex
W4205791193
Cited by
26
References
10
Citations by year
2026: 5 · 2025: 8 · 2024: 8 · 2022: 5
FWCI
0.87
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
glioblastoma, tumor microenvironment, peritumoral tissue, tumor invasion, tumor growth, tumor-associated cells, targeted therapy
MeSH terms
Glioblastoma, Humans, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review